DelMar Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new cancer therapies. Our lead product candidate, VAL-083, is a "first-in-class" small molecule DNA-targeting agent that is currently being evaluated in a biomarker-driven Phase 2 clinical trial for the treatment of Unmethylated MGMT refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. We are also exploring VAL-083 in a Phase 2 trial as a therapy for front-line Unmethylated MGMT GBM and other solid tumors, including ovarian cancer and pediatric CNS tumors.
Suite 720 - 999 West Broadway
Vancouver, B.C., Canada V5Z 1K5
HMO Medical Centers (621491)
Hospital And Medical Service Plans (6324)